Senolytic Compounds

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new medical use for a class of compounds (termed 'peroxygenins' or POGs), which can selectively eliminate senescent cells—a process called senolysis. These compounds work by exploiting the higher oxidative stress and altered metabolism inside senescent cells compared to healthy ones, catalytically generating hydrogen peroxide that kills only the damaged or aged cells, thereby sparing healthy, non-senescent tissue. The patent covers both specific compounds and broad chemical classes, their pharmaceutical compositions, and methods of treatment (in vivo and in vitro) for a range of conditions where removal of senescent cells is beneficial.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of cancer, especially as a follow-up to chemotherapy or radiation to remove therapy-induced senescent tumor cells and reduce relapse risk.
• Management of age-related diseases by clearing pro-inflammatory senescent cells to slow tissue aging and organ dysfunction (e.g., liver fibrosis, COPD).
• Treatment of virus- or infection-induced organ damage, especially in the context of diseases like COVID-19, to reduce inflammation caused by senescent cell accumulation.
• Improvement of physical fitness and health span in aged individuals by reducing systemic senescent cell burden.
• Ex vivo or in vitro cleaning/preparation of organs or cells for transplantation, improving viability and reducing transplant-related inflammation.
• Prevention of certain cancers by eliminating oncogene-induced senescent cells that could otherwise become aggressive tumor stem cells.
• Potential adjunct to autoimmune disease management and chronic inflammation control by removing disease-promoting senescent cells.

BenefitsContent extracted from patent full text and abstract with AI.

• High selectivity for senescent cells, sparing healthy proliferating cells even at therapeutic concentrations.
• Broad applicability ('pan-senolytic')—effective across different triggers of senescence (aging, cancer therapy, viral infection, oncogenic activity).
• Lower risk of toxicity compared to previous uses of related compounds, as effective senolytic doses are much lower than those needed for anti-tumor or antimicrobial action.
• Reduces risk of cancer relapse linked to aggressive stem-like tumor cells emerging from senescence.
• Enables improved patient quality of life and potential extension of healthy lifespan (as shown in animal models).
• Can be combined with standard therapies (such as chemotherapy), providing a complementary and potentially synergistic anti-cancer effect.
• Potential use in regenerative medicine, transplantation, and cellular therapies by eliminating undesired senescent cells from tissues or grafts.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates, amongst others, to the use of a compound according to general formula (I), a derivative of such compound according to any of general formulae (II), (III), or (IV), or a pharmaceutically acceptable salt or hydrate of such compound or derivative as senolytic. The invention further relates to selected compounds according to general formula (I), (II), (III), or (IV).